secwatch.observer — SEC 8-K summary
======================================

Issuer:     BioXcel Therapeutics, Inc. (BTAI)
CIK:        0001720893
Form:       8-K
Filed at:   2022-11-10T23:59:59+00:00
Accession:  0001104659-22-116799
Event type: earnings
Sentiment:  negative
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BioXcel Q3 net loss $41.8M; revenue $137K; IGALMI launch progress with 70-rep sales force by Dec 1
--------------------------------------------------------------------------------

- Net loss of $41.8M for Q3 2022 vs $26.8M loss in Q3 2021; revenue $137K from early product trials.
- Cash and equivalents $232.3M; operating cash used $31.5M in quarter.
- IGALMI commercial: signed largest GPO covering ~50% target beds; expanding sales force to 70 reps by Dec 1 covering 1,700 hospitals.
- Pipeline: TRANQUILITY II and SERENITY III top-line data expected 1H 2023 for agitation indications.
- Phase 1 MDD program completed multiple daily dosing cohorts; top-line results expected 1H 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1720893/000110465922116799/0001104659-22-116799-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1720893/000110465922116799/tm2230135d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-22-116799

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer